“European pharmaceutical research and development. Could a public infrastructure overcome market failures? is available online. The working paper -authored by prof. Massimo Florio and Chiara Pancotti - discusses a new European approach to pharmaceutical policy, exploring the idea of a Europe-wide public infrastructure with budgetary autonomy and home-grown research and development capacity. This organisation would be tasked with building a portfolio of new medicines and related biomedical technologies up to the delivery stage over 30 years, in partnership with third-party research centres at the national or European level and with companies. It would be the world’s most important global player in biomedical innovation.
CSIL working paper draws from selected parts of a study that was originally published by the Panel for the Future of Science and Technology (STOA), managed by the Scientific Foresight Unit of the Directorate for Impact Assessment and European Added Value, within the Directorate-General for Parliamentary Research Services (EPRS) of the European Parliament, with M. Florio as principal investigator. The Working Paper aims to disseminate some findings.
Florio M, Pancotti C (2022), “European pharmaceutical research and development. Could a public infrastructure overcome market failures?”, Working Papers 2022/02, CSIL.